Want to see LFMD full AI Analyst Report?
LFMD Stock Chart & Stats
$3.71
$0.03(0.81%)
At close: 4:00 PM EDT
$3.71
$0.03(0.81%)
Day’s Range― - ―
52-Week Range$2.56 - $12.72
Previous CloseN/A
Volume267.82K
Average Volume (3M)904.85K
Market Cap
$185.71M
Enterprise Value$142.58
Total Cash (Recent Filing)$34.48M
Total Debt (Recent Filing)$6.17M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 05, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding48,362,510
10 Day Avg. Volume701,227
30 Day Avg. Volume904,850
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)6.65
Price to Sales (P/S)0.79
P/FCF Ratio-124.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside156.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$222.05M
Bulls Say, Bears Say
Bulls Say
Recurring Subscriber ScaleA growing base of >365k active telehealth subscribers and record ~42k quarterly adds strengthens recurring revenue predictability and cross-sell opportunity. Durable subscriber scale reduces reliance on one-off acquisition, improves unit economics over time, and supports higher lifetime value across product expansions.
Improving Cash GenerationConsistent positive operating and free cash flow through 2023–TTM and a notable TTM FCF increase signal the company is increasingly funding operations internally. This cash conversion supports sustained investments, reduces financing dependency and provides runway for scaling insurance integrations and pharmacy fulfillment.
Pharmacy & Strategic Pharma PartnershipsA three-year co-marketing partnership to launch an FDA‑approved therapy and an in-house pharmacy capacity (~20k scripts/month, nationwide licensing) deepen product suite and distribution. Structural ties to pharma expand addressable market, accelerate insurance integration, and create durable revenue channels beyond pure digital visits.
Bears Say
Persistent GAAP LossesDespite margin and cash improvements, the company reports recurring GAAP net losses and negative operating profit across periods. Sustained losses undermine return on equity, limit reinvestment capacity without external funding, and maintain long-term pressure on capital structure and investor tolerance.
Revenue VolatilityMaterial swings from growth to a sharp TTM decline indicate dependence on product mix and marketing cadence. Revenue instability complicates multi-quarter planning for provider capacity, pharmacy scale, and insurance partnerships, and raises execution risk that could delay sustainable margin conversion.
Product‑Mix & Marketing Pressure On Unit EconomicsTransitioning from compounded to branded therapies has weakened per‑unit economics in the near term while management runs front‑loaded marketing. This structural mix shift requires scale, payer coverage progress, and RCM optimization before branded units consistently deliver historical margins, prolonging EBITDA recovery.
LifeMD News
LFMD FAQ
What was Lifemd, Inc.’s price range in the past 12 months?
Lifemd, Inc. lowest stock price was $2.56 and its highest was $12.72 in the past 12 months.
What is Lifemd, Inc.’s market cap?
Lifemd, Inc.’s market cap is $185.71M.
When is Lifemd, Inc.’s upcoming earnings report date?
Lifemd, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 5 days.
How were Lifemd, Inc.’s earnings last quarter?
Lifemd, Inc. released its earnings results on May 06, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.206 by $0.006.
Is Lifemd, Inc. overvalued?
According to Wall Street analysts Lifemd, Inc.’s price is currently Undervalued.
Does Lifemd, Inc. pay dividends?
Lifemd, Inc. does not currently pay dividends.
What is Lifemd, Inc.’s EPS estimate?
Lifemd, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Lifemd, Inc. have?
Lifemd, Inc. has 48,362,510 shares outstanding.
What happened to Lifemd, Inc.’s price movement after its last earnings report?
Lifemd, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.206. Following the earnings report the stock price went down -14.801%.
Which hedge fund is a major shareholder of Lifemd, Inc.?
Currently, no hedge funds are holding shares in LFMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LifeMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (156.06% Upside)
$9.50 (156.06% Upside)
Blogger Sentiment
Bullish
LFMD Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 292.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-65.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.74%
Trailing 12-Months
Company Description
Lifemd, Inc.
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical device, and custom-compounded topical treatments for both male and female hair loss. RexMD serves as a men's telehealth brand, providing virtual medical treatment from licensed providers for a wide array of male-specific health needs. LifeMD Primary Care offers a personalized, subscription-based virtual primary care solution, addressing routine, urgent, and chronic health management requirements. This mobile-centric platform integrates remote consultations, medication management, diagnostic services, and imaging referrals. Cleared is a telehealth service dedicated to offering personalized therapies for allergic, asthmatic, and immunological conditions. Nava MD stands as a skincare and tele-dermatology brand catering specifically to women, facilitating virtual access to dermatologists and other specialists for medical treatment. Additionally, the company provides PDFSimpli, a cloud-based software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents online. LifeMD distributes its offerings directly to individuals, via its own e-commerce channels, and through collaborations with external partners. Originally established in 1994 as Conversion Labs, Inc., the company rebranded to LifeMD, Inc. in February 2021 and is headquartered in New York City.
LFMD Company Deck
LFMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive operational narrative: record subscriber additions, strong momentum in weight management and Women’s Health, meaningful gross margin expansion, growing pharmacy and insurance scale, and a clear roadmap to leverage AI for operating leverage. These positives are balanced against near-term profitability pressures from a front-loaded marketing push, a product‑mix transition from compounded to branded drugs that dampened near‑term revenue/unit economics, a wider GAAP net loss, and negative adjusted EBITDA in Q1. Management reaffirmed full-year guidance and outlined drivers for a second‑half EBITDA ramp (insurance coverage expansion, pharmacy economics, cross-sell, and marketing normalization), indicating confidence in the outlook despite short-term investments and transitions.View all LFMD earnings summariesLFMD Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$9.50
▲(156.06% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
17.51% Insiders
10.20% Mutual Funds
0.94% Other Institutional Investors
62.31% Public Companies and
Individual Investors










